Patient info Open main menu

Edronax 4 mg tablets,Reboxetine 4 mg tablets – Summary of Product Characteristics (SmPC) for healthcare professionals

Medicine status: Prescription only (POM) Details

Medicine strength:
4 mg
Contains active substance:
ATC code:
Similar medicines:

Sources: Original (products.mhra.gov.uk)

Summary of Product Characteristics (SmPC) - Edronax 4 mg tablets,Reboxetine 4 mg tablets

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Not applicable

4.2. Posology and method of administration

Not applicable

4.3. Contrain­dications

Not applicable

4.4. Special warnings and precautions for use

Not applicable

4.5. Interactions with other medicinal products and other forms of interaction

4.6. Pregnancy and lactation

Not applicable

4.7. Effects on ability to drive and use machines

Not applicable

4.8. Undesirable effects

Not applicable

4.9. Overdose

Not applicable

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmaco­dynamic properties

Not applicable

5.2. Pharmaco­kinetic properties

Not applicable

5.3. Preclinical safety data

Not applicable

Sources: Original (products.mhra.gov.uk)

Facts about Edronax 4 mg tablets,Reboxetine 4 mg tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Reboxetine
Strength 4 mg
Pharmaceutical form Oral tablet
How is it taken Oral
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)
  1. N Nervous system drugs
    1. N06 Psychoanaleptics
      1. N06A Antidepressants
        1. N06AX Other antidepressants
          1. N06AX18 reboxetine
Marketing authorisation PLPI 19488/0109
Codes BNF 04030400

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.